Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis

BACKGROUND: In March 2020, the Ontario government declared a state of emergency due to the growing risk of COVID-19. In response, new guidance for the management of opioid agonist therapy (OAT) was released, which included the expansion of eligibility for take-home doses. We investigated the impact...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitchen, Sophie A., Campbell, Tonya J., Men, Siyu, Bozinoff, Nikki, Tadrous, Mina, Antoniou, Tony, Wyman, Jennifer, Werb, Dan, Munro, Charlotte, Gomes, Tara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885322/
https://www.ncbi.nlm.nih.gov/pubmed/35272107
http://dx.doi.org/10.1016/j.drugpo.2022.103644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885322/
https://www.ncbi.nlm.nih.gov/pubmed/35272107
http://dx.doi.org/10.1016/j.drugpo.2022.103644

Ejemplares similares